secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001104659-25-071009
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune sells TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds for $55M cash plus up to $30M milestones
--------------------------------------------------------------------------------

- Purchase price $55M cash at close; up to $30M in future regulatory/commercial milestone payments.
- US WorldMeds to offer employment to ~50% of workforce; Adaptimmune to reduce remaining staff by ~62%.
- Pre-tax restructuring costs of ~$7-8M in Q3 2025; CMO, CCO, CSO departing in August.
- Adaptimmune retains preclinical PRAME, CD70, allogeneic assets; restructures to support transition.
- Closing expected before August 4, 2025; financed by Oaktree and Athyrium debt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/0001104659-25-071009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/tm2521829d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-071009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer